Active Ingredient History
Cirmtuzumab is an anti-ROR1 humanised monoclonal antibody. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Immune System Diseases (Phase 3)
Immunoproliferative Disorders (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphatic Diseases (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoproliferative Disorders (Phase 3)
Neoplasms ()
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue